血脂异常全面管理的目标和现状

被引：12

作者：

郑刚

机构：

[1] 天津市第三医院心内科天津市老年病研究所

来源：

中华老年心脑血管病杂志 | 2012年 / 14卷 / 05期

关键词：

血脂异常; 动脉粥样硬化; 胆固醇,LDL; 胆固醇,HDL; 降血脂药; 氯贝酸;

D O I：

暂无

中图分类号：

R589.2 [脂肪代谢障碍];

学科分类号：

100201 [内科学];

摘要：

<正>当前,以动脉粥样硬化为基础的心脑血管病已成为威胁人类健康的头号杀手。导致动脉粥样硬化的重要原因之一是血脂代谢异常,国内血脂异常的发病率为18.6%,全国有1.6亿患者,在北京等大城市及经济发达地区情况可能更为严重。随着人们生活水平的不断提高,健康教育的相对滞后,发病率还将继续上升。由于对血脂异常的危害性认识不足,重视不够,并且血脂异常的临床症状不多,治疗用药又

引用

页码：557 / 560

页数：4

共 12 条

[1]

中国39家大医院动脉粥样硬化性心脑血管病患者他汀类药物应用现状调查.[J].张丹;葛蕾;李静;李希;冯芳;Landray Martin;Armitage Jane;蒋立新;.中华心血管病杂志.2011, 05

[2]

非高密度脂蛋白胆固醇水平与中国人群心血管病发病危险的相关性.[J].任洁;赵冬;刘静;王薇;王淼;孙佳艺;刘军;李岩;齐玥;秦兰萍;吴兆苏;.中华心血管病杂志.2010, 10

[3]

Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention [J].

Sirtori, Cesare R. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (11) :1543-1554

[4]

Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region [J].

Huxley, Rachel R. ;

Barzi, Federica ;

Lam, Tai Hing ;

Czernichow, Sebastien ;

Fang, Xianghua ;

Welborn, Tim ;

Shaw, Jonathan ;

Ueshima, Hirotsugu ;

Zimmet, Paul ;

Jee, Sun Ha ;

Patel, Jeetesh V. ;

Caterson, Ian ;

Perkovic, Vlado ;

Woodward, Mark .

CIRCULATION, 2011, 124 (19) :2056-U82

[5]

ESC/EAS Guidelines for the management of dyslipidaemias.[J].Alberico L. Catapano;Željko Reiner;Guy De Backer;Ian Graham;Marja-Riitta Taskinen;Olov Wiklund;Stefan Agewall;Eduardo Alegria;M. John Chapman;Paul Durrington;Serap Erdine;Julian Halcox;Richard Hobbs;John Kjekshus;Pasquale Perrone Filardi;Gabriele Riccardi;Robert F. Storey;David Wood.Atherosclerosis.2011, 1

[6]

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification.[J].Vimal Ramjee;Laurence S. Sperling;Terry A. Jacobson.Journal of the American College of Cardiology.2011, 5

[7]

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin.[J].Judith Hsia;Jean G. MacFadyen;John Monyak;Paul M. Ridker.Journal of the American College of Cardiology.2011, 16

[8]

A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice [J].

Guo, Yuan-Lin ;

Liu, Jun ;

Li, Jian-Jun ;

Zhu, Cheng-Gang ;

Qing, Ping ;

Jia, Yan-Jun ;

Wu, Na-Qiong ;

Nie, Shao-Ping ;

Li, Zi-Cheng ;

Zeng, He-Song ;

Yang, Ping .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 153 (02) :211-212

[9]

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial.[J].Trevethick Michael$Department of Discovery Biology; Pfizer Global Research and Development; San

[10]

Lipoprotein(a): Medical Treatment Options for an Elusive Molecule [J].

Parhofer, Klaus G. .

CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (09) :871-876

← 1 2 →